Paras S. Minhas,Jeffrey R. Jones,Amira Latif‐Hernandez,Yuki Sugiura,Aarooran S. Durairaj,Takeshi Uenaka,Qian Wang,Siddhita D. Mhatre,Ling Liu,Travis B. Conley,Hannah Ennerfelt,Yoo Jin Jung,Praveena Prasad,Brenita C. Jenkins,Ryan Goodman,Traci Fang Newmeyer,Kelly J. Heard,Austin Kang,Edward N. Wilson,Erik M. Ullian
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer Disease (AD), and recent proteomic studies highlight a disruption of glial carbohydrate metabolism with disease progression. Here, we report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN) in the first step of the kynurenine pathway, rescues hippocampal memory function and plasticity in preclinical models of amyloid and tau pathology by restoring astrocytic metabolic support of neurons. Activation of IDO1 in astrocytes by amyloid-beta